Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Sponsor: AstraZeneca
Listed as NCT01563302, this PHASE1/PHASE2 trial focuses on Advanced Cancers and DLBCL and remains completed. Sponsored by AstraZeneca, it has been updated 10 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 5 earlier versions
-
Jul 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
-
Feb 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Ionis Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .